Protests in Delhi as EU defends Big Pharma

Published on 3 March 2011 at 10:50

“Thousands march in India against EU trade deal,” headlines the EUobserver. With the EU on the verge of concluding a Free Trade Agreement (FTA) with India, its largest trading partner, HIV-positive protesters took to the streets of New Delhi on 2 March concerned that the union is seeking to put an end to the production of affordable life-prolonging drugs. Since negotiations opened in 2007, the EU has pushed for a “data-exclusivity” clause which would protect intellectual property rights with respect to drugs. “European drug manufacturers complain that many of their patented products are frequently undercut by generics produced in India,” the Brussels website notes. Data exclusivity would mean that “clinical trial data filed by one company could not be relied upon by other companies,” critics argues. “As a result, the need for each firm to produce its own clinical trial tests would dramatically increase the price of medicines.” According to Anand Grover, the UN Special Rapporteur on the Right to Health, "It would be a colossal mistake to introduce data exclusivity in India, when millions of people across the globe depend on the country as the pharmacy of the developing world.”

Was this article useful? If so we are delighted! It is freely available because we believe that the right to free and independent information is essential for democracy. But this right is not guaranteed forever, and independence comes at a cost. We need your support in order to continue publishing independent, multilingual news for all Europeans. Discover our membership offers and their exclusive benefits and become a member of our community now!

Are you a news organisation, a business, an association or a foundation? Check out our bespoke editorial and translation services.

Support independent European journalism

European democracy needs independent media. Join our community!

On the same topic